Lovaltech has joined the Infectious Diseases Cluster's pre-acceleration program
ID cluster supports LVT-NEXUS structuring in industry, regulation and intellectual property
Lovaltech has been selected by the Infectious Diseases Cluster (ID Cluster), a key player in the France 2030 strategy, for its pre-acceleration program.
The support focuses on the industrial, regulatory and intellectual property structuring of LVT-NEXUS.
LVT-NEXUS, is our mucal delivery platform, based on LVT-ME, our proprietary muco-excipient. The platform is designed to be combined with various payloads and is in clinical evaluation with its first product, LVT-001. The goal is to establish it as a benchmark technology platform in Europe for future nasal-administration vaccine candidates.